未登录

M

Mayur K. Ladumor

Merck and Co.

H指数:12

被引数:379

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network

推进全球药事公平：ASCPT发展、监管与结果网络的思考

Clinical Pharmacology & Therapeutics

IF5.5

2026-02-130

OAAI

The JPET Editorial Fellowship: Opening the Blinds to the Peer Review and Editorial Process

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2024-05-010

OAAI

Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-10-201

OA

Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2022-12-207

OA

The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans

ADME科学的下一个前沿: 预测人类基于转运蛋白的药物处置，组织浓度和药物-药物相互作用

PHARMACOLOGY & THERAPEUTICS

IF12.5

2022-10-0124

OAAI

A Tribute to Professor Saranjit Singh-A Critical Thinker, Innovator, Mentor, and Educator

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2022-05-010

PRE

Exploration of the Plausible Mechanism of Ethambutol Induced Ocular Toxicity by Using Proteomics Informed Physiologically Based Pharmacokinetic (PBPK) Modeling

PHARMACEUTICAL RESEARCH

IF4.3

2022-03-172

PRE

Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide

IF4.3

2020-12-1519

OAAI

In vitro evaluation of reactive nature of E- and Z-guggulsterones and their metabolites in human liver microsomes using UHPLC-Orbitrap mass spectrometer

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2020-07-014

PREAI

A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation

SCIENTIFIC REPORTS

IF3.9

2019-07-0444

OAAI

Stability behaviour of antiretroviral drugs and their combinations. 9: Identification of incompatible excipients

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2019-03-019

PREAI

Study of degradation behaviour of montelukast sodium and its marketed formulation in oxidative and accelerated test conditions and prediction of physicochemical and ADMET properties of its degradation products using ADMET Predictor™

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2018-09-0120

PREAI